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Stromal tumors of uncertain malignant potential (STUMP) are rare diagnoses in the evaluation of
elevated PSA. The management of STUMP in the setting of an elevated PSA is challenging, as STUMP
may have a benign clinical course. In this report, we describe a patient who was found to have a PSA
>500 ng/ml and a large STUMP. We review the critical ﬁndings and review the relevant literature on
diagnosis and management strategies for patients with STUMP.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The diagnosis of STUMP presents a diagnostic and management
challenge for the practicing urologist. These tumors exhibit atypical
stromal proliferation and can exhibit an unpredictable clinical
course. Furthermore, the clinical and laboratory ﬁndings associated
with STUMPmay be nonspeciﬁc, leading to delayed diagnosis. Thus,
the decision-making surrounding treatment of STUMP remains
poorly understood.Case presentation
The patient is a 63 year old healthy African American male
without a family history of prostate cancer who was referred by his
PCP with a history of benign prostate biopsies and a rising prostate
speciﬁc antigen (PSA) level. Review of his medical records revealed
a PSA of 58 ng/ml in 2004; 75 ng/ml in 2006; 106 ng/ml in 2009;
and 90 ng/ml in 2011. Following his PSA in 2011, his local urologist
performed a transrectal prostate biopsy, which revealed patchy
fascicular spindle cell proliferation with CD34 positivity and nega-
tive PR, actin, desmin, and pankeratin on immunohistochemistry.
Computed tomography and technetium bone scan failed to identify
any evidence of metastatic disease. He continued to be followedUrological Institute, Johns
D 21287, USA. Tel.: þ1 443
. Johnson).
Inc. This is an open access article uconservatively with a PSA of 267 ng/ml in 2014. By the time he
presented to our clinic, his PSA was 504 ng/ml. His International
Prostate Symptom Score (IPSS) was 8 of 35 and he denied any
bothersome lower urinary tract symptoms.
He underwent a prostate MRI, which conﬁrmed a markedly
enlarged prostate with an estimated volume of 290 cc. The differ-
ential diagnosis on MRI was sarcoma, STUMP, and adenocarcinoma
(PIRADS 5/5) based on abnormal signal on T2-weighted imaging,
ADC maps, and DCE throughout the gland (Fig. 1). There was sus-
pected extraprostatic disease. His biopsy showed only subtle
changes in the stroma without any prostatic carcinoma or stromal
sarcoma identiﬁed (Fig. 2). A follow up bone scan showed degen-
erative changes with 2 nonspeciﬁc areas of osseous uptake in the
fourth ribs and thoracic spine that were reported on a similar
imaging study in 2011 (Fig. 3).
The ﬁndings were discussed with the patient including the
potential for cystectomy and/or pelvic exenteration. He chose not to
undergo surgery, recognizing the uncertain prognosis and
possibility of bowel and urinary obstruction in the future.Discussion
The diagnosis of prostate STUMP includes tumors with a spec-
trum of stromal proliferation and clinical presentations. As a result,
diagnosis and management remains challenging. In an analysis of
50 patients with STUMP, stromal sarcoma, or mixed pathology,
Herawi and Epstein identiﬁed urinary obstructive symptoms,
abnormal digital rectal exam, hematuria, hematospermia, and rectalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Coronal (A) and sagittal (B) T2 magnetic resonance imaging demonstrating a large STUMP (green arrows) replacing the majority of the prostate and displacing the urinary
bladder (red arrows).
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ranged from27 to 83 years and elevated PSAwas amotivating factor
for biopsy in 11 of 50 cases. Reported tumor sizes ranged from
0.7 cm to 18 cm and weights ranged from 26 g to 1044 g.
Histologically, prostatic STUMP may have a variety of
growth patterns and there are neither sensitive nor speciﬁc
immunohistochemical markers. Indeed, Pan et al compared chro-
mosomal imbalances between STUMP and stromal sarcomas. Of 14
specimens, common chromosomal losses included chromosome
13 (10 cases), chromosome 14 (9 cases), and chromosome
10 (7 cases).2 There were no observed differences in the
chromosomal imbalances between STUMP and stromal sarcoma.
Guadin et al proposed 4 subtypes e degenerative atypia, hyper-
cellular, mixed type, and phyllodes type.3 In a review of 70 STUMP
with a glandular component, Nagar and Epstein identiﬁed glandular
crowding as the most common ﬁndings, seen in 50% of the tumors.4
The most common subtype seen was degenerative atypia, seen in
61% of the tumors. Seventeen percent of the tumors had glands that
were identical to the uninvolved benign prostatic tissue. In the
patients evaluated by Hewari and Epstein, prostate adenocarcinoma
was found in 17 of 50 cases.1 Of the 15 patients who were treated
with radical prostatectomy, 11 patients had adenocarcinoma as an
incidental ﬁnding that was distinct from the stromal tumor.
Radiographically, there is limited literature on the appearance of
STUMP. Nevertheless, these tumorsmay have varying ﬁndings, based
on histological subtype and may be located in the peripheral and
transition zones. Tumors that are multi-loculated, or have a necroticFigure 2. (A) Low power and (B) high power images of the transrectal prostate biopsy sho
sarcoma.or mucinous component may have higher T2 signal intensity.5 Solid
lesions may be heterogeneous in appearance. Despite the atypical
appearance, caremust be taken to determine the location of themass
and its potential involvement of other pelvic structures.
Treatmentof STUMPremains challenging. As apotentially benign
entity, these tumors may be adherent to neighboring structures,
making resection difﬁcult and requiring extensive surgery for com-
plete resection.1 STUMP may harbor stromal sarcoma, making
incomplete resection a poor choice from an oncologic perspective.
Previous efforts to manage these tumors with non-deﬁnitive
resection have resulted in locally recurrent disease, reported in up
to 46% of patients, or metastatic disease.1,3 STUMP without stromal
sarcoma may follow a benign course. However, in the cohort re-
ported byHewari and Epstein, 1 of 7 patients withmixed STUMP and
sarcoma developed abdominal metastases and died of disease after
almost 10 years following cystoprostatectomy. Another had para-
aortic and bone metastases following cystoprostatectomy and was
alive 23 years following treatment. The remaining had no evidence
of disease following treatment.
Conclusion
STUMP is a rare pathological ﬁnding with a variable clinical
presentation and unpredictable clinical course. To the authors’
knowledge, this represents the ﬁrst reported case of an STUMPwith
a PSA >500 ng/ml. Clinicians must be aware that STUMP may
resemble or contain prostate stromal sarcoma. There are nowing normal-appearing prostate glands and stroma without evidence of carcinoma or
Figure 3. Whole body 99-Tm bone scan demonstrating non-speciﬁc activity in the T5 vertebra and bilateral posterior fourth ribs.
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after thorough discussion on the risks and beneﬁts of intervention.
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